Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Female Reproductive SystemDRG 759-infections-female-reproductive-system-without-cc-mcc
    Ask Trek AI about this page

    Infections, Female Reproductive System without CC/MCC: Inpatient Reimbursement Overview

    DRG 759 addresses inpatient admissions for infections of the female reproductive system without a Complication or Comorbidity or a Major Complication or Comorbidity, focusing on cases of lower severity. It matters for inpatient reimbursement because grouping influences the Medicare Severity Diagnosis-Related Group payment and thus hospital revenue for these episodes of care.

    Customize your policy alerts

    Sign up for drg 759 policy alerts

    Get alerted when payer policies referencing 759 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 759 Overview

    DRG 759 covers inpatient admissions for infections of the female reproductive system that do not carry a Complication or Comorbidity or a Major Complication or Comorbidity. Typical cases include pelvic inflammatory disease and other gynecologic infections treated medically or with minor procedures. This Diagnosis-Related Group matters for Medicare payment because it groups similar clinical severity into a single payment weight that affects hospital reimbursement for these admissions. Accurate coding of principal diagnosis and any secondary diagnoses determines assignment to this Diagnosis-Related Group and the associated Medicare Severity Diagnosis-Related Group payment.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Acute antimicrobial optimization trials: studies testing protocols to shorten time-to-appropriate therapy, compare empiric antibiotic regimens, or evaluate rapid diagnostic-guided escalation/de-escalation strategies in hospitalized women with pelvic inflammatory disease, tubo-ovarian abscess, endometritis, or other reproductive tract infections without major comorbidities. These trials enroll adult reproductive‑age and peri‑menopausal women admitted for acute infection and measure time to clinical resolution, length of stay, and antibiotic exposure; they are relevant because faster, targeted therapy can reduce complications, inpatient days, and antimicrobial costs. Providers and payers benefit from evidence that supports safe, resource‑efficient in-hospital management pathways and stewardship that lower readmission and resistance costs.
    • Comparative effectiveness studies of interventional vs. conservative management for localized abscesses: prospective cohort or randomized studies comparing percutaneous or transvaginal drainage plus antibiotics versus antibiotics alone for small to moderate adnexal or tubo‑ovarian abscesses in women without severe systemic disease. The population includes hospitalized patients whose infections meet imaging criteria for abscess but lack major organ dysfunction, assessing outcomes such as treatment failure, need for surgery, hospital length of stay, and post-discharge complications. This research informs decisions about procedural utilization, potential avoidance of operative interventions, and cost-effectiveness relevant to inpatient resource allocation and reimbursement under this DRG.
    • Post-discharge outcomes and quality-of-care studies: observational or pragmatic trials evaluating follow‑up strategies, patient education, and outpatient care coordination to prevent recurrence and readmission among women discharged after treatment for reproductive tract infections. These studies track adherence to follow‑up, rates of recurrent infection, fertility-related outcomes, and total episodic cost of care across 30–90 days, targeting patients without CC/MCC to identify gaps between inpatient treatment and outpatient recovery. Findings are important to payers and hospitals aiming to reduce readmissions, improve long‑term reproductive health outcomes, and align discharge planning with value-based reimbursement models.

    Related Codes

    734-PELVIC-EVISCERATION-RADICAL-HYSTERECTOMY-AND-RADICAL-VULVECTOMY-WITH-CC-MCC

    Pelvic Evisceration, Radical Hysterectomy and Radical Vulvectomy with CC/MCC: Inpatient Reimbursement Overview

    735-PELVIC-EVISCERATION-RADICAL-HYSTERECTOMY-AND-RADICAL-VULVECTOMY-WITHOUT-CC-MCC

    Pelvic Evisceration, Radical Hysterectomy and Radical Vulvectomy: Inpatient Reimbursement Overview

    736-UTERINE-AND-ADNEXA-PROCEDURES-FOR-OVARIAN-OR-ADNEXAL-MALIGNANCY-WITH-MCC

    Uterine and Adnexa Procedures for Ovarian or Adnexal Malignancy with MCC: Inpatient Reimbursement Overview

    737-UTERINE-AND-ADNEXA-PROCEDURES-FOR-OVARIAN-OR-ADNEXAL-MALIGNANCY-WITH-CC

    Uterine and Adnexa Procedures for Ovarian or Adnexal Malignancy with CC: Inpatient Reimbursement Overview

    738-UTERINE-AND-ADNEXA-PROCEDURES-FOR-OVARIAN-OR-ADNEXAL-MALIGNANCY-WITHOUT-CC-MCC

    Uterine and Adnexa Procedures for Ovarian or Adnexal Malignancy without CC/MCC: Inpatient Reimbursement Overview

    739-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-OVARIAN-AND-NON-ADNEXAL-MALIGNANCY-WITH-MCC

    Uterine and Adnexa Procedures for Non-Ovarian and Non-Adnexal Malignancy with MCC: Inpatient Reimbursement Overview

    740-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-OVARIAN-AND-NON-ADNEXAL-MALIGNANCY-WITH-CC

    Uterine and Adnexa Procedures for Non-Ovarian and Non-Adnexal Malignancy with CC: Inpatient Reimbursement Overview

    741-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-OVARIAN-AND-NON-ADNEXAL-MALIGNANCY-WITHOUT-CC-MCC

    Uterine and Adnexa Procedures for Non-Ovarian and Non-Adnexal Malignancy without CC/MCC: Inpatient Reimbursement Overview

    742-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-MALIGNANCY-WITH-CC-MCC

    Uterine and Adnexa Procedures for Non-Malignancy with CC/MCC: Inpatient Reimbursement Overview

    743-UTERINE-AND-ADNEXA-PROCEDURES-FOR-NON-MALIGNANCY-WITHOUT-CC-MCC

    Uterine and Adnexa Procedures for Non-Malignancy without CC/MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 24

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.